True Wealth Design’s RAPT Therapeutics RAPT Stock Holding History

True Wealth Design’s Portfolio RAPT Stock Details RAPT Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2025 Q2	–	Sell	-35	Closed	-$342	–	2779
2025 Q1	$342	Buy	+35	New	+$344	﹤0.01%	1722

Other funds holding RAPT

Medicxi Ventures Management St. Helier, Jersey $982M AUM 210.17% 1-Year Est. Return

OrbiMed New York $5.05B AUM 125.28% 1-Year Est. Return

TCG Crossover Management Palo Alto, California $3.5B AUM 1,165.83% 1-Year Est. Return

Foresite Capital Management VI Larkspur, California $460M AUM 261.77% 1-Year Est. Return

RTW Investments New York $10B AUM 135.35% 1-Year Est. Return

Column Group San Francisco, California $101M AUM 290.34% 1-Year Est. Return

BVF Inc San Francisco, California $3.14B AUM 249.53% 1-Year Est. Return

Nantahala Capital Management New Canaan, Connecticut $2.72B AUM 121.58% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

ADAR1 Capital Management Austin, Texas $1.7B AUM 340.85% 1-Year Est. Return

True Wealth Design's RAPT Position: Q2 2025 in Review

True Wealth Design sold out of RAPT Therapeutics (RAPT) in Q2 2025, closing a stake of 35 shares — an estimated $342 sold.

True Wealth Design first reported a position in RAPT in Q1 2025 and held it in 1 quarter. The position peaked at $342 in Q1 2025. 50 funds tracked by Wall St. Rank hold RAPT as of Q2 2025.

True Wealth Design reported no remaining RAPT Therapeutics position as of Q2 2025 after selling out during the quarter.
True Wealth Design sold 35 RAPT Therapeutics shares in Q2 2025, an estimated $342.
True Wealth Design first reported a position in RAPT Therapeutics in Q1 2025 and held it in 1 quarter.
True Wealth Design's RAPT Therapeutics position peaked at $342 in Q1 2025.
50 funds tracked by Wall St. Rank held RAPT Therapeutics as of Q2 2025.

Based on True Wealth Design's 13F filing for Q2 2025, filed 6 Aug 2025.